Human Genome kept at buy by Merrill

Merrill Lynch analyst Hari Sambasivam maintained Human Genome Sciences, Inc. at a buy after the company's analyst day where the company focused on the start of phase 3 Albuferon and LymphoStat-B trials and an increased focus on cash management. Management projected an average cash burn rate of $150 million over the next few years, significantly lower than prior years, according to the analyst. Merrill's revised loss per share estimates for 2007 are $1.76 from $1.93 and for 2008 are $0.54 from $0.65. Shares of the Rockville, Md.-based biopharmaceutical company were up 28 cents, or 2.25%, at $12.73. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.